Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT01809691
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Interventions
Name:
TAK-700
Type:
DRUG
Description:
300 mg, PO, twice daily
Name:
Bicalutamide
Type:
DRUG
Description:
50 mg, PO, q daily
Primary Outcomes
Measure:
Overall Survival
TimeFrame:
Duration of treatment and follow-up until death or 9 years after study start
Description:
Overall survival is defined as the time from random assignment to the date of death from any cause
Trial Information
NCT ID
NCT01809691
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
SWOG Cancer Research Network
Last Updated
December 15, 2025